

Financial Tear Sheet

Corporate Profile

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.

We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.

Stock Information

DERM (Common Stock)

Exchange NASDAQ GS (US Dollar)

Financial Status Indicator C

Price \$22.93

Change (%) ▼ 0.49 (2.09%)

Volume 126,637

52 Week High \$38.75

52 Week Low \$21.39

Market Cap \$974,070,003

Rolling EPS -2.65

PE Ratio 0

Shares Outstanding 41,591,375

Data as of 08/18/17 4:00 p.m. ET



Recent News

08/08/17

Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab

08/07/17

Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update

07/25/17

UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/17/17	4
08/17/17	4
08/17/17	4
08/17/17	4

Corporate Governance

Thomas G. Wiggans	Founder & Chief Executive Officer
Eugene A. Bauer, M.D.	Founder & Chief Medical Officer
Christine Conroy	Senior Vice President, Regulatory Affairs
Janice Drew, MPH	Senior Vice President, Clinical & Project Management
Christopher Griffith	Founder & Vice President, Corporate Development & Strategy
Andrew Guggenhime	Chief Operating Officer & Chief Financial Officer
Hans Hofland, Ph.D.	Vice President, Research
Delphine Imbert, Ph.D.	Senior Vice President, Pharmaceutical Sciences
Luis Peña	Chief Development Officer
Christine Ring, Ph.D.	Vice President, Legal

Data provided by Nasdaq. Minimum 15 minutes delayed.